Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX). See What Biden and the Democrats Just Did To YOUR Money. CLDX Stock Summary With a one year PEG ratio of 954.15, Celldex Therapeutics Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings … Celldex Appoints Freddy A. Jimenez, Esq. View Celldex Therapeutics' earnings history. Celldex Therapeutics (CLDX) stock price, charts, trades & the US's most popular discussion forums. Get the latest Celldex Therapeutics, Inc. (CLDX) stock news and headlines to help you in your trading and investing decisions. View our earnings forecast for Celldex Therapeutics. This suggests a possible upside of 39.9% from the stock's current price. At the close of trading, the stock’s price was $25.38, to imply a decline of -3.42% or -$0.9 in intraday trading. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. CLDX | Complete Celldex Therapeutics Inc. stock news by MarketWatch. Currency in USD, Trade prices are not sourced from all markets. Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX.". Celldex Therapeutics is headquartered at 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. Analyst Report: Baxter International Inc. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Compare Top Brokerages Here. GlobeNewsWire - 1 year ago Celldex … Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. Celldex Therapeutics Inc's upside potential (average analyst target price relative to current … DOW 30,932.37. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings. HAMPTON, N.J. , Dec. 09, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the first patient has been dosed in its open label clinical trial in cold contact … Find real-time CLDX - Celldex Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Celldex Therapeutics has received 576 “outperform” votes. How can you protect your money and all you’ve worked for from this reset? View the real-time CLDX price chart on Robinhood and decide if you want to buy or sell commission-free. The 1-15 reverse split was announced on Friday, February 8th 2019. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. When you find (and hold) a... Investors need to pay close attention to Celldex (CLDX) stock based on the movements in the options market lately. There are currently 3 buy ratings for the stock. Celldex Therapeutics' stock was trading at $2.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Oil is Dead Money: Green-Energy Stocks Are Booming. High institutional ownership can be a signal of strong market trust in this company. The biopharmaceutical company earns $-50,880,000.00 in net income (profit) each year or ($3.28) on an earnings per share basis. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Celldex … Celldex Therapeutics had a negative trailing twelve-month return on equity of 30.93% and a negative net margin of 1,069.42%. Learn about financial terms, types of investments, trading strategies and more. View analyst ratings for Celldex Therapeutics or view top-rated stocks. Since then, CLDX shares have increased by 1,150.2% and is now trading at $25.38. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Celldex Therapeutics has only been the subject of 2 research reports in the past 90 days. CLDX stock was acquired by a variety of institutional investors in the last quarter, including Artal Group S.A., Candriam Luxembourg S.C.A., Price T Rowe Associates Inc. MD, ExodusPoint Capital Management LP, Swiss National Bank, Acuta Capital Partners LLC, Squarepoint Ops LLC, and Silverarc Capital Management LLC. On average, they expect Celldex Therapeutics' stock price to reach $35.50 in the next twelve months. Export data to Excel for your own analysis. Free real-time prices, trades, and chat. Learn more. CDX-0159 is a humanized monoclonal antibody that binds the KIT receptor with high specificity and potently inhibits its activity. It develops CDX-1140, an agonist human monoclonal antibody, which is being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in metastatic solid tumors and B cell lymphomas; CDX-3379, a monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-0159, a Phase I monoclonal antibody that binds the KIT receptor and inhibits its activity; and CDX-527, a bispecific antibody that uses anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway. Celldex Therapeutics does not currently pay a dividend. Get short term trading ideas from the MarketBeat Idea Engine. Celldex Therapeutics, Inc. (CLDX) today announced that the Company will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 2:20 p.m. You may vote once every thirty days. The U.S. House of Representatives voted to let the IMF circulate what could be a new elite-controlled reserve currency. To see all exchange delays and terms of use please see disclaimer. Shares of Celldex rose earlier this week following the presentation of results from a trial with CDX-0159 and 32 healthy patients. Do Options Traders Know Something About Celldex (CLDX) Stock We Don't? Celldex Therapeutics has a market capitalization of $1.00 billion and generates $3.57 million in revenue each year. (0.87%). The P/E ratio of Celldex Therapeutics is -11.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Get daily stock ideas top-performing Wall Street analysts. Celldex Therapeutics has a P/B Ratio of 4.35. All rights reserved. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. The MarketWatch News Department was not involved in the creation of this content. Celldex Therapeutics Inc. [NASDAQ: CLDX] closed the trading session at $4.80 on 06/10/20. Our pipeline includes immunotherapies and other targeted … Vote “Underperform” if you believe CLDX will underperform the S&P 500 over the long term. You can opt out at any time. Earnings for Celldex Therapeutics are expected to grow in the coming year, from ($1.81) to ($1.46) per share. In the past three months, Celldex Therapeutics insiders have sold more of their company's stock than they have bought. 3 Undervalued Mid-caps with Good Upside. The company is evaluating CDX-0159 in two ongoing Phase 1b trials in patients with chronic spontaneous urticaria and chronic inducible urticaria. The CLDX … Some companies that are related to Celldex Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS). CLDX has a higher number of analysts covering the stock than 11.89% of stocks in the mid market cap category. View which stocks have been most impacted by COVID-19. Celldex Therapeutics's stock reverse split before market open on Monday, February 11th 2019. In a Phase 1a single-dose, healthy volunteer study, CDX-0159 demonstrated durable plasma tryptase reductions indicative of systemic mast cell suppression/ablation. View all of CLDX's competitors. The day’s price range saw the stock hit a low of $3.2835, while the highest price level was … CLDX, Celldex Therapeutics Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Celldex Therapeutics Inc Stock Quote: CLDX Stock News… In comparing Celldex Therapeutics, Inc. (CLDX)’s stock with other industry players reveals that stock’s current price change of +4.01% and that of +940.08% over the past 12 months is in better position with that of Bristol-Myers Squibb Company (BMY) which saw its stock … © 2021 Verizon Media. For many, the main point of investing in the stock market is to achieve spectacular returns. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton; Amgen Inc.; Yale University; and MedImmune, LLC. CLDX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, TSP Capital Management Group LLC, Hussman Strategic Advisors Inc., and Charles Schwab Investment Management Inc.. View insider buying and selling activity for Celldex Therapeutics or view top insider-selling stocks. All rights reserved. Celldex Therapeutics, Inc. (NASDAQ:CLDX) posted its earnings results on Thursday, November, 5th. Subscribe to Premium to view Fair Value for CLDX. Cronos Stock … Hives (urticaria) are red, itchy welts that result from a skin reaction. Identify stocks that meet your criteria using seven unique stock screeners. Celldex Therapeutics Inc (NASDAQ: CLDX) will expand the clinical development of CDX-0159 into prurigo nodularis (PN), a chronic skin disease characterized by the development of hard, intensely itchy (pruritic) nodules on the skin. MarketBeat just released five new trading ideas, but Celldex Therapeutics wasn't one of them. The Top 3 Stocks to Buy in March 2021. Learn more. View institutional ownership trends for Celldex Therapeutics. Our Accessibility Statement Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. Company insiders that own Celldex Therapeutics stock include Anthony S Marucci, Diane C Young, James J Marino, Margo Heath-Chiozzi, Richard M Wright, Samuel Bates Martin and Tibor Keler. View our full suite of financial calendars and market data tables, all for free. Here’s a brand new clean energy innovator, currently undiscovered at $1.35 per share, that’s advancing some of the largest green-energy assets in North America. Only 2.40% of the stock of Celldex Therapeutics is held by insiders. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 See the latest Celldex Therapeutics (CLDX) stock analysis, price, forecast, news and more. Celldex Therapeutics' management team includes the following people: Shameful! Celldex Therapeutics, Inc. (CLDX) announced today that the Company will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2 at 4:20 pm ET. View which stocks have been most impacted by COVID-19. In December last year, the company dosed the first patient in a chronic inducible urticaria study. View insider buying and selling activity for Celldex Therapeutics or or view top insider-buying stocks. The official website for Celldex Therapeutics is www.celldex.com. ), Celldex Therapeutics has received 352 “underperform” votes. A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex … According to analysts' consensus price target of $35.50, Celldex Therapeutics has a forecasted upside of 39.9% from its current price of $25.38. The biopharmaceutical company reported ($0.36) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.36). Learn everything you need to know about successful options trading with this three-part video course. Vote “Outperform” if you believe CLDX will outperform the S&P 500 over the long term. The biopharmaceutical company can be reached via phone at 908-200-7500 or via email at [email protected]. Specifically, they have bought $0.00 in company stock and sold $387,684.00 in company stock. Founder, Chief Scientific Officer & Exec. Please log in to your account or sign up in order to add this asset to your watchlist. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey. Company insiders that have bought Celldex Therapeutics stock in the last two years include Anthony S Marucci, Diane C Young, James J Marino, Margo Heath-Chiozzi, Samuel Bates Martin, and Tibor Keler. Shares of CLDX can be purchased through any online brokerage account. A chronic spontaneous urticaria study was initiated in October last year, with results expected in the second half of 2021. MarketBeat's community ratings are surveys of what our community members think about Celldex Therapeutics and other stocks. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. View analysts' price targets for Celldex Therapeutics or view top-rated stocks among Wall Street analysts. Thinking about buying or selling stock in CLDX? Its exchange rate could effectively devalue the U.S. dollars in your pocket and your savings. Celldex Therapeutics employs 127 workers across the globe. View the latest Celldex Therapeutics Inc. (CLDX) stock price, news, historical charts, analyst ratings and financial information from WSJ. QQQ 314.14. S&P 500 3,811.15. Benzinga does not provide investment advice. Celldex Therapeutics, Inc. (CLDX) Quote Overview » News » Celldex Therapeutics, Inc. (CLDX) Zacks ... Investors need to pay close attention to Celldex (CLDX) stock based on the … Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. View breaking news headlines for CLDX stock from trusted media outlets at MarketBeat. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Want to see which stocks are moving? See more from BenzingaClick here for options trades from BenzingaRevance Therapeutics' DaxibotulinumtoxinA For Injection Improves Muscle Tone In Mid-Stage Upper Limb SpasticityCompugen To Test COM701, Opdivo Combination In Solid Tumor Settings© 2021 Benzinga.com. Celldex Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 25th 2021. The KIT receptor tyrosine kinase is expressed in various cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. Celldex Therapeutics does not have a long track record of dividend growth. With oil fracking now dead money under Biden, the Smart Money is flowing into Green-Energy stocks with everyday investors making $millions. When did Celldex Therapeutics' stock … All rights reserved. Receive a free world-class investing education from MarketBeat. Looking for new stock ideas? Celldex Therapeutics has received a consensus rating of Buy. © American Consumer News, LLC dba MarketBeat® 2010-2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. Celldex Therapeutics news and CLDX price. VP, Start Your Risk-Free Trial Subscription Here, Editor of top German newspaper suspended in compliance probe, Timing key in consulting deal between FirstEnergy, regulator, You Must Recognize Your Own Achievements First Before Expecting Others To, The Latest: Paris may face new lockdown as ICUs fill up, 'Big burden' for schools trying to give kids internet access, The Latest: Pakistan imposes partial lockdown in some areas, Three Mall Retailers For Your Reopening Watchlist, 3 Growth Stocks with Above Market Dividend Yields, 3 Best Stocks to Buy That You’ve Probably Never Heard Of, Ferroglobe Will Get a Big Lift From Demand For Silcon Wafers, Blue Bird Stock is a Dual Tailwinds EV and Re-Opening Play, Nautilus Stock is a Pullback Buying Opportunity Here, The Launch of Truforma Should Send Zomedica to An All-Time High, Defi Markets Pause But New Highs Are In Sight, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, Celldex Therapeutics Announces Fireside Chat Presentation at the H.C. Wainwright Global Life Sciences Conference, Celldex Therapeutics To Test CDX-0159 In Chronic Itchy Skin Disorder, Celldex Therapeutics to Expand Development of CDX-0159 into Prurigo Nodularis (PN), Celldex Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference, Announcing: Celldex Therapeutics (NASDAQ:CLDX) Stock Soared An Exciting 736% In The Last Year. The biopharmaceutical company had revenue of $0.67 million for the quarter, compared to analysts' expectations of $0.29 million. Find the latest news headlines from Celldex Therapeutics, Inc. (CLDX) at Nasdaq.com. The company also holds exclusive rights to CDX-301 and CD40 ligand, which are immune modulating molecules that increase the numbers and activity of immune cells that control immune responses. HAMPTON, N.J., Feb. 08, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) (“Celldex” or the “Company”) today announced that its Board of Directors has approved a one-for-fifteen reverse stock split of its common stock … Considering analysts have assigned the stock … The consensus among Wall Street equities research analysts is that investors should "buy" Celldex Therapeutics stock. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. ET. (Add your “underperform” vote.). See what's happening in the market right now with MarketBeat's real-time news feed. A high-level overview of Celldex Therapeutics, Inc. (CLDX) stock. One share of CLDX stock can currently be purchased for approximately $25.38. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. Sign-up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Celldex Therapeutics' stock is owned by a variety of retail and institutional investors. View real-time stock prices and stock quotes for a full financial overview. 80.15% of the stock of Celldex Therapeutics is held by institutions. Wall Street analysts have given Celldex Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Since then, CLDX shares have increased by 1,092.6% and is now trading at $24.21. Celldex Therapeutics' stock was trading at $2.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqCM - NasdaqCM Real Time Price. Price Action: CLDX closed 1.3% higher at $28.25 on Monday. Their forecasts range from $35.00 to $36.00. Initial data is expected at the end of the first quarter of 2021. Celldex Therapeutics has received 62.07% “outperform” votes from our community. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Fundamental company data provided by Zacks Investment Research. About Us Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Celldex (CLDX) Soars: Stock Adds 10% in Session Celldex (CLDX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes. Get the latest news and real-time alerts from Celldex Therapeutics, Inc. (CLDX) stock at Seeking Alpha. Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s traded shares stood at 516,171 during the last session, with the company’s beta value hitting 3.06. Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s beta value is holding at 2.68, while the average true range (ATR) indicator is currently reading 1.5. (Add your “outperform” vote. Celldex Therapeutics (NASDAQ:CLDX) had its price target upped by HC Wainwright from $16.00 to $25.00 in a report released on Monday, The Fly reports. An investor that had 100 shares of Celldex Therapeutics stock prior to the reverse split would have 7 shares after the split. Do Not Sell My Information. 3 brokers have issued 12-month price objectives for Celldex Therapeutics' shares. CLDX … P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. View which stocks are hot on social media with MarketBeat's trending stocks report. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. as Senior Vice President and General Counsel, These 5 Small-Cap Healthcare Stocks Gained the Most in 2020, Celldex Doses First Patient in Phase 1b Study of CDX-0159 in Chronic Inducible Urticaria, Celldex Therapeutics to Present at 3rd Annual Evercore ISI HealthCONx Conference, Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation, Celldex Presents Data from Oncology Portfolio at SITC 2020, Celldex Provides Corporate Update and Reports Third Quarter 2020 Results, Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates, Celldex Initiates Early-Stage Antibody Study for Skin Disorder, Dosing underway in Celldex Therapeutics' CDX-0159 early-stage skin disorder study, Celldex Therapeutics Says First Patient Dosed In Phase 1b Study Of CDX-0159 - Quick Facts, Why Celldex Has Been A Big Winner In 2020, Celldex Therapeutics Announces Closing of $150.0 Million Public Offering of Common Stock Including Full Exercise of, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Top institutional investors include Acuta Capital Partners LLC (4.11%), Renaissance Technologies LLC (2.65%), BlackRock Inc. (2.18%), TSP Capital Management Group LLC (1.02%), Artal Group S.A. (1.01%) and Candriam Luxembourg S.C.A.